Literature DB >> 30256515

The effect of steroid treatment on weight in nonambulatory males with Duchenne muscular dystrophy.

Molly M Lamb1, Bo Cai2, Julie Royer3, Shree Pandya4, Aida Soim5, Rodolfo Valdez6, Carolyn DiGuiseppi1, Katherine James1, Nedra Whitehead7, Holly Peay7, Swamy Y Venkatesh8, Dennis Matthews9.   

Abstract

To describe the long-term effect of steroid treatment on weight in nonambulatory males with Duchenne Muscular Dystrophy (DMD), we identified 392 males age 7-29 years with 4,512 weights collected after ambulation loss (176 steroid-naïve and 216 treated with steroids ≥6 months) from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Comparisons were made between the weight growth curves for steroid-naïve males with DMD, steroid-treated males with DMD, and the US pediatric male population. Using linear mixed-effects models adjusted for race/ethnicity and birth year, we evaluated the association between weight-for-age and steroid treatment characteristics (age at initiation, dosing interval, cumulative duration, cumulative dose, type). The weight growth curves for steroid-naïve and steroid-treated nonambulatory males with DMD were wider than the US pediatric male growth curves. Mean weight-for-age z scores were lower in both steroid-naïve (mean = -1.3) and steroid-treated (mean = -0.02) nonambulatory males with DMD, compared to the US pediatric male population. Longer treatment duration and greater cumulative dose were significantly associated with lower mean weight-for-age z scores. Providers should consider the effect of steroid treatment on weight when making postambulation treatment decisions for males with DMD.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  corticosteroids; muscular dystrophy; nonambulatory; weight

Mesh:

Substances:

Year:  2018        PMID: 30256515      PMCID: PMC7533648          DOI: 10.1002/ajmg.a.40517

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  46 in total

1.  Trends in survival from muscular dystrophy in England and Wales and impact on respiratory services.

Authors:  L D Calvert; T M McKeever; W J M Kinnear; J R Britton
Journal:  Respir Med       Date:  2005-10-28       Impact factor: 3.415

Review 2.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

3.  The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology.

Authors:  Lisa A Miller; Paul A Romitti; Christopher Cunniff; Charlotte Druschel; Katherine D Mathews; F John Meaney; Dennis Matthews; Jiji Kantamneni; Zhen-Fang Feng; Nancy Zemblidge; Timothy M Miller; Jennifer Andrews; Deborah Fox; Emma Ciafaloni; Shree Pandya; April Montgomery; Aileen Kenneson
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2006-11

4.  Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.

Authors:  Ernesto A C Beenakker; Johanna M Fock; Marja J Van Tol; Natalia M Maurits; Hendrik M Koopman; Oebele F Brouwer; Johannes H Van der Hoeven
Journal:  Arch Neurol       Date:  2005-01

5.  Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  R T Moxley; S Ashwal; S Pandya; A Connolly; J Florence; K Mathews; L Baumbach; C McDonald; M Sussman; C Wade
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

6.  High body mass index for age among US children and adolescents, 2003-2006.

Authors:  Cynthia L Ogden; Margaret D Carroll; Katherine M Flegal
Journal:  JAMA       Date:  2008-05-28       Impact factor: 56.272

7.  Long-term benefit from prednisone therapy in Duchenne muscular dystrophy.

Authors:  G M Fenichel; J M Florence; A Pestronk; J R Mendell; R T Moxley; R C Griggs; M H Brooke; J P Miller; J Robison; W King
Journal:  Neurology       Date:  1991-12       Impact factor: 9.910

8.  Truncal fat distribution correlates with decreased vital capacity in Duchenne muscular dystrophy.

Authors:  Craig A Canapari; Nick Barrowman; Lynda Hoey; Scott W Walker; Elise Townsend; Brian S Tseng; Sherri L Katz
Journal:  Pediatr Pulmonol       Date:  2014-03-18

9.  Does Body Mass Index Predict Premature Cardiomyopathy Onset for Duchenne Muscular Dystrophy?

Authors:  Meghann McKane; Jonathan H Soslow; Meng Xu; Benjamin R Saville; James C Slaughter; W Bryan Burnette; Larry W Markham
Journal:  J Child Neurol       Date:  2017-01-13       Impact factor: 1.987

10.  Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.

Authors:  Valeria Ricotti; Deborah A Ridout; Elaine Scott; Ros Quinlivan; Stephanie A Robb; Adnan Y Manzur; Francesco Muntoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-12-18       Impact factor: 10.154

View more
  2 in total

1.  Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state.

Authors:  Kristin M Conway; Scott D Grosse; Lijing Ouyang; Natalie Street; Paul A Romitti
Journal:  Muscle Nerve       Date:  2022-02-09       Impact factor: 3.852

2.  The Relationship between Obesity and Clinical Outcomes in Young People with Duchenne Muscular Dystrophy.

Authors:  Natassja Billich; Justine Adams; Kate Carroll; Helen Truby; Maureen Evans; Monique M Ryan; Zoe E Davidson
Journal:  Nutrients       Date:  2022-08-12       Impact factor: 6.706

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.